Want to see BEAT full AI Analyst Report?
BEAT Stock Chart & Stats
$2.56
$0.00(0.00%)
At close: 4:00 PM EST
$2.56
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.54 - $4.00
Previous CloseN/A
Volume12.23K
Average Volume (3M)89.04K
Market Cap
$34.72M
Enterprise Value$22.64M
Total Cash (Recent Filing)$2.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 06, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding55,506,836
10 Day Avg. Volume76,817
30 Day Avg. Volume89,039
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-943.18
Enterprise Value/Ebitda-1.12
Forecast
1Y Price Target
$3.83Price Target Upside49.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$1.83M
Bulls Say, Bears Say
Bulls Say
Extended Runway From FinancingA completed $11.5M offering and pro forma cash of ~$12.4M materially extends runway into 2027, reducing near-term refinancing pressure and enabling completion of pivotal pilots, prototype commercialization and AI development. This gives management time to de-risk regulatory and commercial milestones before the next funding need.
Strategic Shift To Licensing ModelPivoting to a licensing-led model lowers capital intensity and operating costs, leverages partners’ distribution scale, and accelerates global adoption. A lean implementation team and founder-as-operator can focus on IP, algorithms and partner integrations, improving capital efficiency and long-term scalability of revenue streams.
Clinical And Regulatory De‑riskingExisting FDA clearances plus active pilots (ALIGN‑ACS enrollment ahead of schedule and patch pilot initiation) materially advance regulatory and clinical validation. These durable milestones underpin potential label expansion, enable AI training on real-world data, and strengthen commercial conversations with health systems and OEMs over the medium term.
Bears Say
Pre‑revenue With Sustained LossesA prolonged pre‑revenue profile with annual net losses near $13–$21M and ~ $20M TTM means the business must continue funding operations until commercial scale. Persistent cash losses impede internal reinvestment, heighten dilution risk from future financings, and lengthen the timeline to sustainable, self-funded growth.
Sharply Weakened Equity CushionA collapsing equity base to roughly $0.6M TTM removes a margin of safety and raises solvency concerns if cash consumption persists. Even with no debt, low shareholder equity constrains strategic optionality, makes future capital raises more dilutive, and reduces attractiveness to partners or acquirers evaluating balance‑sheet strength.
Listing Compliance And Financing RiskA formal Nasdaq minimum bid‑price deficiency is a structural governance and liquidity risk: potential delisting would impair trading liquidity, complicate capital raises and could deter commercial partners. The compliance timeline adds persistent execution pressure that can affect strategic flexibility and investor confidence.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.54 and its highest was $4.00 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $34.72M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Aug 06, 2026 which is in 28 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on May 13, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.015.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.09.
How many shares outstanding does HeartBeam have?
HeartBeam has 55,506,836 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went up 2.97%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartBeam Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.83 (49.74% Upside)
$3.83 (49.74% Upside)
Insider Transactions
Bought Shares
Worth $905.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.97%
12-Months-Change
Fundamentals
Return on Equity
-1034.04%
Trailing 12-Months
Asset Growth
-56.86%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.
BEAT Company Deck
BEAT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational progress across multiple fronts — financing closed to extend runway, prototype completion and pilot initiations for the 12‑lead patch, enrollment momentum in ALIGN‑ACS, strategic Mount Sinai AI collaboration, and initial commercial anchor partnerships in four target geographies. At the same time, the company remains an early‑stage commercial operation with a Q1 net loss of $4.7M, limited near‑term revenue, reliance on future studies and regulatory approvals for MI indication, and continued cash consumption (though operating cash burn improved 19% YoY and full‑year outflow guidance was reduced to under $16M). On balance, the highlights (funding, clinical progress, partnerships, prototype, AI collaboration, reduced burn) outweigh the lowlights (losses, limited revenue, regulatory and adoption risk), yielding a cautiously positive outlook as the company advances toward de‑risking key milestones.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$3.83
▲(49.74% Upside)
Technical Analysis
Ownership Overview
10.47% Insiders
2.61% Mutual Funds
1.69% Other Institutional Investors
81.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---